Publicacións en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (43)

2024

  1. Cross-Validation of Risk Scores for Patients Undergoing Transcatheter Edge-to-Edge Repair for Mitral Regurgitation

    Journal of the Society for Cardiovascular Angiography and Interventions, Vol. 3, Núm. 2

2023

  1. Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials

    The American journal of cardiology, Vol. 205, pp. 321-324

  2. Impact of Complete Revascularization in the ISCHEMIA Trial

    Journal of the American College of Cardiology, Vol. 82, Núm. 12, pp. 1175-1188

  3. Survival after Invasive or Conservative Management of Stable Coronary Disease

    Circulation, Vol. 147, Núm. 1, pp. 8-19

  4. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events

    Journal of Clinical Lipidology, Vol. 17, Núm. 5, pp. 602-611

  5. Transaxillary versus transfemoral access as default access in TAVI: A propensity matched analysis

    International Journal of Cardiology

2022

  1. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 3, pp. 291-301

2021

  1. Final five-year results of the REMEDEE Registry: Real-world experience with the dual-therapy COMBO stent

    Catheterization and Cardiovascular Interventions, Vol. 98, Núm. 3, pp. 503-510

  2. Glycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabetes

    Journal of the American College of Cardiology, Vol. 77, Núm. 22, pp. 2777-2791

  3. Mitral valve prolapse morphofunctional features by cardiovascular magnetic resonance: more than just a valvular disease

    Journal of Cardiovascular Magnetic Resonance, Vol. 23, Núm. 1

  4. Mortality associated with cardiovascular disease in patients with COVID-19

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 30-38

  5. One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration

    Cardiovascular Drugs and Therapy, Vol. 35, Núm. 2, pp. 309-320

  6. Severe Valvular Heart Disease and COVID-19: Results from the Multicenter International Valve Disease Registry

    Structural Heart, Vol. 5, Núm. 4, pp. 424-426

  7. Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration

    Catheterization and Cardiovascular Interventions, Vol. 97, Núm. 5, pp. 797-804

  8. Triglycerides and Residual Atherosclerotic Risk

    Journal of the American College of Cardiology, Vol. 77, Núm. 24, pp. 3031-3041

2020

  1. 1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry

    IJC Heart and Vasculature, Vol. 31

  2. 1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration

    Cardiovascular Revascularization Medicine, Vol. 21, Núm. 12, pp. 1542-1547

  3. 1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration

    International Journal of Cardiology, Vol. 307, pp. 17-23

  4. Comparison of One-Year Outcomes in Patients >75 Versus ≤75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry)

    American Journal of Cardiology, Vol. 127, pp. 1-8

  5. Estimation of the major cardiovascular events prevention with Inclisiran

    Atherosclerosis, Vol. 313, pp. 76-80